Orchid Pharma Standalone Quarterly Results in Rs. Cr. Dec’24 Sep’24 Dec’23 Net Sales/Income from operations 217.34 222.70 220.59 EBITDA stands at Rs. 36.31 crore in December 2024 down 16.24% from Rs. 43.35 crore in Dec 2023. Orchid Pharma shares closed at 943.60 on February 13, 2025 (NSE) and has given -32.07% returns over the last 6 months and -15.66% over last 12 months. The company has a market capitalization of Rs. 2,000 crore. It has a Pledged/Encumbered – Number of shares (Crores) — — — – Per. of Shares (as a % of the total sh. of prom. and promoter group) — — — – per. share of the company. The Company has a Non-encumbered – number of shares of Crores — –. — -per. shares ( as a percentage of the. total Share Cap. of theCompany) — – — — Per. Share Holding (%) — — — Promoters and Promoter Group Shareholding — –, — — Other Expenses 44.13 41.27 44.07 P/L Before Other Inc. , Int., Excpt. Items & Tax 17.76 20.96 26.65 Other Income 9.94 7.96 7.44 P/ l After Tax from Ordinary Activities 23.91 25.63 30.55
